Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Genfit SA (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
GNFT
Nasdaq
8731
https://www.genfit.fr/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Genfit SA (ADR)
GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents
- Apr 15th, 2024 8:10 pm
GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F
- Apr 5th, 2024 6:00 pm
GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
- Apr 4th, 2024 8:10 pm
GENFIT Announces Revenues and Cash Position as of December 31, 2023
- Feb 29th, 2024 9:10 pm
GENFIT Announces 2024 Financial Calendar
- Jan 15th, 2024 9:10 pm
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
- Jan 11th, 2024 9:10 pm
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)
- Dec 8th, 2023 6:55 am
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
- Dec 7th, 2023 10:15 am
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials
- Dec 6th, 2023 4:30 pm
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023
- Nov 16th, 2023 9:10 pm
GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
- Nov 13th, 2023 9:30 pm
GENFIT Reports Third Quarter 2023 Financial Information
- Nov 9th, 2023 9:10 pm
GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023
- Nov 2nd, 2023 9:10 pm
GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology
- Sep 26th, 2023 8:10 pm
GENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
- Sep 26th, 2023 1:55 pm
GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update
- Sep 20th, 2023 8:10 pm
GENFIT to Participate in Upcoming Investor Conferences
- Sep 5th, 2023 8:10 pm
GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications
- Aug 10th, 2023 8:10 pm
Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients
- Jun 30th, 2023 8:03 pm
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
- Jun 30th, 2023 5:00 am
Scroll